All In Biotech

Drug Trial Radar · NCT03901118

Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer

A Multi-center, Phase Ⅱ Clinical Trial of Chiauranib Plus Chemotherapy in Relapsed/Refractory Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Mar 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

47

Actual

Start

Jul 1, 2019

Primary completion

Dec 18, 2020

Study completion Dec 18, 2020

Sponsor

Lead sponsor
Chipscreen Biosciences, Ltd.Industry
Sponsor type
Industry
First posted
Apr 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial will evaluate the efficacy and safety of chiauranib added to chemotherapy in patients with relapsed or refractory ovarian cancer, in the meantime, explore the pharmacokinetics characteristic after the combined treatment.

Conditions

  • Ovarian Cancer

Interventions

  • chiauranibDrug

    in the phase of pilot trial, 25mg orally once daily; in the formal phase, 50mg orally once daily

  • etoposideDrug

    50mg orally once daily for 21 days, 7 days off, every 28 days for a cycle, 6 cycles at most

  • paclitaxelDrug

    60mg/m2, i.v infusion on day 1, 8 and 15, every 21 days for a cycle, 6 cycles at most

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. progression-free survival (PFS)Time frame: assessed up to 1 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.